NMNihal Martis

Nihal Martis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nihal Martis has a total of 296 co-authors. Here are the top co-authors by number of shared publications:

  • Paul Coppo

    Sorbonne Université, AP‐HP, Hôpital Saint‐Antoine, Service d'Hématologie Clinique et Thérapie Cellulaire Paris France

    4 shared publications
  • Anne-Sophie Morin

    23Service de Medecine Interne, Jean Verdier Hôpital, Assistance Publique-Hôpitaux de Paris, Bondy, France

    3 shared publications
  • Antoinette Perlat

    Department of Internal Medicine and Clinical Immunology, CHU Rennes , Rennes

    3 shared publications
  • Benjamin Terrier

    Service de Médecine Interne, Hôpital Cochin, Paris, France

    3 shared publications
  • Guillaume Moulis

    Service de Médecine Interne, Centre Hospitalier Universitaire de Toulouse, Toulouse, France

    3 shared publications
  • Lionel Galicier

    National Reference Center for Castleman disease, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France

    3 shared publications

Latest Publications

  • Intensive Care Management of ANCA-associated Vasculitides: a Narrative Review

    by Elisa Bazin, Lucas Morand, Nihal Martis

    Purpose of Review Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides, particularly granulomatosis with polyangiitis and microscopic polyangiitis, are rare but severe systemic diseases frequently requiring intensive care unit (ICU) admission due to life-threatening renal and pulmonary involvement. Despite advances in immunosuppressive therapy, these patients remain at high risk of mortality and end-stage kidney disease, with prognosis driven by organ failure (notably diffuse alveolar haemorrhage [DAH]) and treatment-related complications such as infection. ICU management is complex and relies on rapid diagnosis, aggressive induction therapy, and tailored organ support. Recent Findings Current remission-induction strategies centre on high-dose glucocorticoids combined with cyclophosphamide or rituximab, with growing emphasis on minimizing steroid exposure. Plasma exchange (PLEX), once widely used for severe renal disease and DAH, remains debated, although selected high-risk subgroups may still derive benefit. Summary Optimal management in the ICU requires a multidisciplinary approach, including careful selection of immunosuppressive regimens, individualized use of adjunctive therapies such as PLEX and the management of infectious complications. Advances in supportive care, including lung-protective ventilation, renal replacement therapy, and extracorporeal support, have improved short-term outcomes. However, significant uncertainty persists regarding optimal therapeutic strategies in the critically ill populations, highlighting the need for further research and phenotype-driven approaches.

  • Spectrum and significance of 18F-FDG-PET/CT abnormalities in VEXAS syndrome

    by Albrecht Betrains, Vincent Jachiet, Yannick Dieudonné, Jeremie Dion, Estibaliz Lazaro, Alexis Jean, Claire de Moreuil, Samuel Ardois, Sylvie Grosleron, Jean-Benoit Arlet, et al.

    Objective: VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a recently identified adult-onset autoinflammatory disorder caused by somatic mutations in UBA1. It is characterized by heterogeneous inflammatory and haematological manifestations, making diagnosis challenging. 18F-FDG-PET/CT imaging, which identifies metabolic activity associated with inflammation and malignancy, is often performed during the diagnostic work-up. However, its utility in VEXAS syndrome remains unclear. Methods: We conducted a multicentre retrospective observational study of patients with genetically-confirmed VEXAS syndrome who underwent 18F-FDG-PET/CT imaging. Clinical, laboratory and imaging data were collected, and 18F-FDG-PET/CT findings were analysed according to disease activity, myelodysplastic syndrome status and mortality. Qualitative 18F-FDG-PET/CT interpretations were based on local nuclear medicine reports. Results: A total of 125 18F-FDG-PET/CT scans were analysed in 66 patients. Bone marrow (83%) and lymph nodes (53%) were the most frequent sites of abnormal FDG uptake, with combinations of bone marrow, lungs, lymph nodes and spleen being the most common patterns. Pulmonary (38%) and vascular involvement (11%) were also observed. The number of organs with abnormal FDG uptake was significantly higher in patients with active disease compared with remission (median 2 vs 1 abnormal sites, P < 0.001). However, 90% of scans performed during presumed clinical remission showed persistent abnormalities, especially in the bone marrow (57%). Conclusion: 18F-FDG-PET/CT imaging reveals frequent but non-specific abnormalities in VEXAS syndrome, with persistent bone marrow hypermetabolism suggesting subclinical disease activity. While 18F-FDG-PET/CT may have limited diagnostic utility, it holds potential for disease monitoring.

  • Open Access

    VE/VCO2 at ventilatory threshold and peak VO2 in CPET studies of patients with scleroderma-associated PAH: A systematic review and meta-analyses

    by Julie Better, Sylvie Leroy, Maarten K. Ninaber, Georgia Trakada, Bilge Kesikburun, Stephan Rosenkranz, Ralph Ewert, Dirk Habedank, Daniel Dumitrescu, Yanis Kouchit, et al.


  • Glandular Manifestations of the Head and Neck in ANCA-Associated Vasculitides: Data from a National Cohort and Systematic Review

    by Nicolas Duhamel, Xavier Puéchal, Thomas Le Gallou, Julie Chezel, Alban Deroux, Céline Roussin, Jérémy Keraen, Claire De Moreuil, Pierre-André Jarrot, Mathieu Gerfaud-Valentin, et al.

    Glandular involvement of the head and neck is an extremely rare feature in ANCA-associated vasculitis (AAV). The objective was to describe glandular involvement in AAV by analysing data from a national cohort and comparing the findings to those from a systematic literature review. A multicentric retrospective study was conducted through a survey promoted by the French Vasculitis Study Group and included patients aged ≥ 16 years who met the ACR/EULAR classification criteria for AAV and had lachrymal and/or salivary involvement. Demographic, clinical and biological findings were analysed and pooled with data from a MEDLINE review of the literature since inception until June 5, 2024. The study population included 20 patients with a median age of 52 years (IQR, 44.5–57.5 years). Granulomatosis with polyangiitis (n = 17) and PR3-ANCA (n = 10) were the most represented. Parotitis (n = 9) and dacryoadenitis (n = 8) were found to precede and/or were present at AAV onset and recurrences. All patients received glucocorticoids, usually in combination with immunosuppressants. The systematic review identified another 67 cases. Pooled analysis of all cases (n = 87) showed that salivary gland involvement was not only frequently associated with ENT features (OR = 4.01 (95% CI, 1.30–13.06; p < 0.01)), but also with PR3-ANCA positivity (OR = 3.34 (95% CI, 1.09–11.34; p = 0.02)). Lachrymal involvement was associated with concomitant ophthalmological signs (OR = 3.93 (95% CI, 1.31–12.14; p < 0.01)). Glandular involvement of the head and neck is a rare but identifiable manifestation of active AAV. Knowledge of this uncommon presentation refines clinical assessment for optimal management of patients with AAV.


  • Open Access

    Anti‐ ADAMTS13 Antibodies Trajectory is Associated With ADAMTS13 Recovery in Immune‐Mediated TTP

    by Marie Robert, Arthur Mageau, Ygal Benhamou, François Provôt, Jehane Fadlallah, Lionel Galicier, Elie Azoulay, Hafid Ait‐Oufella, Tomas Urbina, Pascale Poullin, et al.

    Current triplet regimens associating therapeutic plasma exchange (TPE), immunosuppression with corticosteroids and rituximab, and caplacizumab have dramatically improved the outcome of immune‐mediated thrombotic thrombocytopenic purpura (iTTP). However, nearly half of the patients require extended caplacizumab treatment (i.e., > 30 days) due to persistent ADAMTS13 deficiency, raising cost and tolerance concerns. Therefore, we investigated whether anti‐ADAMTS13 antibodies titer and their trajectory during the acute phase of the disease could predict ADAMTS13 improvement (i.e., activity ≥ 20% before day‐30 post‐TPE). From a cohort of 286 patients receiving the triplet regimen, we identified on diagnosis a cut‐off value for anti‐ADAMTS13 IgG antibodies of 90.5 U/mL, with a modest discriminating ability (AUC: 0.57) for predicting long‐term response, precluding its use to guide therapeutic strategies. Nonetheless, the analysis of anti‐ADAMTS13 IgG antibodies titer trajectory from diagnosis revealed that the proportion of iTTP patients with ADAMTS13 activity improvement was higher in patients who decreased (Dec+) their antibodies titer within the 7–14 days interval post‐TPE compared to those without decrease (Dec−) (65% vs. 25% of cases, respectively, p < 0.001), a finding confirmed in a validation cohort ( N = 51). These results highlight the possibility of intensifying immunosuppression in an early period post‐TPE to shorten time to ADAMTS13 activity recovery. Close monitoring of anti‐ADAMTS13 antibodies titer may guide immunomodulation strategies, including additional courses of B‐cell depleting agents when appropriate.


  • Long-term follow-up of the STOPAGO study

    by Adrien Cottu, Stéphanie Guillet, Jean-François Viallard, Etienne Rivière, Stéphane Cheze, Delphine Gobert, Antoine Neel, Julie Graveleau, Jean-Pierre Marolleau, François Lefrere, et al.

    In an open prospective, multicenter study enrolling 48 selected patients with chronic immune thrombocytopenia who achieved complete response for 1 year on thrombopoietin receptor agonists, half of the patients maintained a sustained response off treatment 4 years after treatment discontinuation.


  • Inclusion-body myositis associated with Sjögren’s disease: clinical characteristics and comparison with other Sjögren-associated myositis

    by Quentin Astouati, Thomas Machet, Camille Houssais, Jean-Baptiste Noury, Yves Allenbach, Laure Gallay, Baptiste Quere, Florence Assan, Olivier Benveniste, Jonathan Broner, et al.

    To describe the characteristics of patients with Sjögren’s disease (SjD) and inclusion-body myositis (IBM), and how they compare to SjD patients with other inflammatory myopathies (IM). Patients were retrospectively recruited from 13 French centers and included if they met the ACR/EULAR criteria for SjD and for IM. They were categorized as SjD-IBM if sub-criteria for IBM were met, or as SjD-other IM if not. SjD-IBM patients (n = 22) were mostly females (86%), with a median [Q1; Q3] age of 54 [38.5; 64] years at SjD diagnosis, and 62 [46.5; 70] years at first IBM symptoms. Although most patients displayed glandular and immunological abnormalities, additional extra-glandular manifestations were uncommon, resulting in moderate disease activity at SjD diagnosis (ESSDAI 5.5 [1; 7.8]). Classic IBM features were frequent, such as progressive symptom onset (59%), asymmetrical (27%) and distal (32%) involvements, dysphagia (41%), low CPK (386.5 [221.8; 670.5] UI/l) and CRP (3.0 [3; 8.5] mg/l) levels. Immunosuppressants were reported as efficient in 55% of cases. Compared with SjD-IBM patients, SjD patients with other IM (n = 50) were significantly younger, displayed more frequent additional extra-glandular disease, higher ESSDAI score (11 [3; 30]), shorter delay between SjD diagnosis and myositis onset (0 [-0.5; 26]), more frequent CPK values over 1000 UI/l (36%), and less frequent classic IBM features. IBM can occur in SjD patients, with muscle features reminiscent of classic sporadic IBM characteristics, but mostly affecting women. In SjD patients with muscle involvement, extra-glandular manifestations, high ESSDAI score, elevated CPK values, and shorter delay after SjD diagnosis plead against IBM.


  • Open Access

    Four clinical and biological phenotypes in antiphospholipid syndrome: a cluster analysis of 174 patients with antinuclear antibody tests

    by Marie Ottavi, Pierre Toulon, Barbara Casolla, Nihal Martis

    Introduction: Antiphospholipid syndrome (APS) is an autoimmune thrombotic disease with various systemic presentations. This study aimed to identify homogeneous groups of patients based on a non-supervised hierarchical cluster analysis and assess the rate of relapse associated with antinuclear antibodies (ANA).Methods: This retrospective observational study enrolled patients, over a 90-month period, who had APS as defined by the 2006 Sydney classification criteria, and for whom ANA workup was performed. Agglomerative unsupervised hierarchical clustering was conducted to classify patients into subgroups using 24 variables reflecting a range of clinical and biological baseline features associated with APS.Results: Hundred and seventy-four patients were included and were categorized into four phenotypes. Cluster 1 (n=73) associated mostly middle-aged men with risk factors for cardiovascular disease. Obstetrical APS with low-risk thrombosis made up cluster 2 (n=25). Patients with venous thromboembolism (VTE), microvascular findings and double/triple positive APL antibodies (50%) were represented in cluster 3 (n=33). Whereas cluster 4 (n=43) characterized a predominantly female subpopulation with positive ANA and systemic lupus (n=23) that exhibited a high thrombotic risk and more frequent relapses (n=38) (p<0.001).Conclusions: This study identified four homogenous groups of patients with APS listed as: i) cardiovascular and arterial risk, ii) obstetrical, iii) VTE and microvascular, and iv) ANA-positive APS. We found that ANA-positivity was associated with higher rates of relapse. Applying ANA status to classification criteria could constitute a novel approach to tailoring management for APS, based on phenotypic patterns and risk assessment.


  • Une dermatose linéaire aux avant-bras

    by T. Nerson, E. Castela, N. Leccia, N. Martis